NYSE:HRC

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Hill-Rom Holdings, Inc. operates as a medical technology company worldwide. More Details


Snowflake Analysis

Solid track record with adequate balance sheet.


Similar Companies

Share Price & News

How has Hill-Rom Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: HRC is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: HRC's weekly volatility (4%) has been stable over the past year.


Market Performance


7 Day Return

-1.8%

HRC

-0.2%

US Medical Equipment

2.8%

US Market


1 Year Return

-10.7%

HRC

17.8%

US Medical Equipment

20.9%

US Market

Return vs Industry: HRC underperformed the US Medical Equipment industry which returned 17.7% over the past year.

Return vs Market: HRC underperformed the US Market which returned 20.7% over the past year.


Shareholder returns

HRCIndustryMarket
7 Day-1.8%-0.2%2.8%
30 Day5.1%4.8%11.1%
90 Day2.0%3.6%6.5%
1 Year-9.9%-10.7%18.8%17.8%23.6%20.9%
3 Year16.7%13.6%69.7%65.3%47.3%37.6%
5 Year105.4%95.4%136.9%118.7%94.3%72.9%

Long-Term Price Volatility Vs. Market

How volatile is Hill-Rom Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Hill-Rom Holdings undervalued compared to its fair value and its price relative to the market?

12.5%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: HRC ($95.7) is trading below our estimate of fair value ($109.52)

Significantly Below Fair Value: HRC is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: HRC is good value based on its PE Ratio (28.6x) compared to the US Medical Equipment industry average (48.8x).

PE vs Market: HRC is poor value based on its PE Ratio (28.6x) compared to the US market (19.7x).


Price to Earnings Growth Ratio

PEG Ratio: HRC is poor value based on its PEG Ratio (2.2x)


Price to Book Ratio

PB vs Industry: HRC is good value based on its PB Ratio (3.7x) compared to the US Medical Equipment industry average (4.4x).


Next Steps

Future Growth

How is Hill-Rom Holdings forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

13.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: HRC's forecast earnings growth (13.1% per year) is above the savings rate (2.2%).

Earnings vs Market: HRC's earnings (13.1% per year) are forecast to grow slower than the US market (22% per year).

High Growth Earnings: HRC's earnings are forecast to grow, but not significantly.

Revenue vs Market: HRC's revenue (2.6% per year) is forecast to grow slower than the US market (10.2% per year).

High Growth Revenue: HRC's revenue (2.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: HRC's Return on Equity is forecast to be high in 3 years time (20.8%)


Next Steps

Past Performance

How has Hill-Rom Holdings performed over the past 5 years?

20.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: HRC has high quality earnings.

Growing Profit Margin: HRC's current net profit margins (7.7%) are higher than last year (5.2%).


Past Earnings Growth Analysis

Earnings Trend: HRC's earnings have grown significantly by 20.5% per year over the past 5 years.

Accelerating Growth: HRC's earnings growth over the past year (46.5%) exceeds its 5-year average (20.5% per year).

Earnings vs Industry: HRC earnings growth over the past year (46.5%) exceeded the Medical Equipment industry 0.2%.


Return on Equity

High ROE: HRC's Return on Equity (12.9%) is considered low.


Next Steps

Financial Health

How is Hill-Rom Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: HRC's short term assets ($1.4B) exceed its short term liabilities ($952.2M).

Long Term Liabilities: HRC's short term assets ($1.4B) do not cover its long term liabilities ($2.0B).


Debt to Equity History and Analysis

Debt Level: HRC's debt to equity ratio (111.5%) is considered high.

Reducing Debt: HRC's debt to equity ratio has reduced from 193% to 111.5% over the past 5 years.

Debt Coverage: HRC's debt is well covered by operating cash flow (25%).

Interest Coverage: HRC's interest payments on its debt are well covered by EBIT (5.4x coverage).


Balance Sheet


Next Steps

Dividend

What is Hill-Rom Holdings's current dividend yield, its reliability and sustainability?

0.92%

Current Dividend Yield


Upcoming Dividend Payment


Dividend Yield vs Market

Notable Dividend: HRC's dividend (0.92%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.47%).

High Dividend: HRC's dividend (0.92%) is low compared to the top 25% of dividend payers in the US market (4.08%).


Stability and Growth of Payments

Stable Dividend: HRC's dividends per share have been stable in the past 10 years.

Growing Dividend: HRC's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (26%), HRC's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of HRC's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.6yrs

Average management tenure


CEO

John Groetelaars (53 yo)

2.5yrs

Tenure

US$7,326,160

Compensation

Mr. John P. Groetelaars serves as President, Chief Executive Officer and Director of Hill-Rom Holdings Inc. since May 14, 2018. He previously served in a variety of progressive roles at C.R. Bard during hi...


CEO Compensation Analysis

Compensation vs Market: John's total compensation ($USD7.33M) is about average for companies of similar size in the US market ($USD6.90M).

Compensation vs Earnings: John's compensation has increased by more than 20% in the past year.


Leadership Team

NamePositionTenureCompensationOwnership
John Groetelaars
President2.5yrsUS$7.33m0.025%
$ 1.6m
Barbara Bodem
Senior VP & CFO1.92yrsUS$3.14m0.0058%
$ 371.5k
Deborah Rasin
Senior VP4.83yrsUS$1.94m0.048%
$ 3.1m
Andreas Frank
Senior VP & President of Front Line Care business1.92yrsUS$2.02m0.025%
$ 1.6m
Paul Johnson
Senior VP & President of Patient Support Systems4yrsUS$2.14m0.0093%
$ 595.3k
Timothy Lawrence
Senior Vice President of Operations3.17yrsno datano data
Richard Wagner
VP, Controller & CAO2.5yrsno data0.0048%
$ 309.5k
Brian Lawrence
CTO & Senior VP9.92yrsno datano data
Sue-Jean Lin
Chief Information Officer & Senior VP4.83yrsno datano data
Mary Ladone
Senior Vice President of Corporate Developmentno datano data0.018%
$ 1.1m
Ilana Shulman
Chief Compliance Officer6yrsno datano data
Howard Karesh
Vice President of Corporate Communicationsno datano datano data

3.6yrs

Average Tenure

52yo

Average Age

Experienced Management: HRC's management team is considered experienced (3.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
John Groetelaars
President2.5yrsUS$7.33m0.025%
$ 1.6m
James Giertz
Independent Director10.92yrsUS$270.70k0.0030%
$ 191.2k
Ronald Malone
Independent Director13.33yrsUS$274.70kno data
William Dempsey
Independent Chairman of the Board2.67yrsUS$382.15k0.0080%
$ 514.7k
Nancy Schlichting
Independent Director3.67yrsUS$281.70kno data
Gary Ellis
Independent Director3.08yrsUS$276.45kno data
Felicia Norwood
Independent Director0.75yrno datano data
William Kucheman
Independent Director7.67yrsUS$268.70kno data
Stacy Seng
Independent Director5.67yrsUS$264.20kno data
Mary Garrett
Independent Director3.67yrsUS$267.70k0.00045%
$ 28.8k
Gregory Moore
Independent Director1.5yrsUS$190.71kno data

3.7yrs

Average Tenure

62yo

Average Age

Experienced Board: HRC's board of directors are considered experienced (3.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Hill-Rom Holdings, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Hill-Rom Holdings, Inc.
  • Ticker: HRC
  • Exchange: NYSE
  • Founded: 1915
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$6.394b
  • Shares outstanding: 66.81m
  • Website: https://www.hillrom.com

Number of Employees


Location

  • Hill-Rom Holdings, Inc.
  • 130 East Randolph Street
  • Suite 1000
  • Chicago
  • Illinois
  • 60601
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
HRCNYSE (New York Stock Exchange)YesCommon StockUSUSDJul 1971
HB9DB (Deutsche Boerse AG)YesCommon StockDEEURJul 1971

Biography

Hill-Rom Holdings, Inc. operates as a medical technology company worldwide. It operates through Patient Support Systems, Front Line Care, and Surgical Solutions segments. The company offers medical surgica...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/29 23:06
End of Day Share Price2020/11/27 00:00
Earnings2020/09/30
Annual Earnings2020/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.